Showing posts with label health. Show all posts
Showing posts with label health. Show all posts

Sunday, July 29, 2012

Drainage Oil From Another Perspective

The case of drainage oil from China maybe old news for some readers but it is a new one for me, having heard about it from a friend last week. I think that it is a case worth mentioning if we are to consider that China’s food industry continues to draw flaks. However, I would like to end this post with some thought-provoking statements.

For those of you who need a refresher or have never heard about this case, drainage oil is a term used to describe used cooking oil that is poured into the drainage. Rumor has it that some oil recyclers literally collect them from the drainage, process and then sell them back as recycled cooking oil.

According to the media, this is a serious problem in China but is it really true? Could it just have been a case that is blown out of proportion in light of the negative publicity surrounding China’s food industry? If this idea of recycling cooking oil from the drainage has been carried out in the developed countries, would it have been viewed negatively? Would it instead have been singled out as an innovative technique?

Sunday, July 31, 2011

Should the Government leave the provision of medical services to the private sector?

For a while, there have been debates on whether the Government should leave the provision of medical services to the private sector. With spending cuts and debt reduction in the horizon for many developed economies, this issue has once again caught the interest of policymakers.

In my opinion, there are certainly several advantages for public provision of medical services. Letting the market does the work has the potential of causing less attention to be put in areas that are important from the perspective of a nation but less so in the eyes of the revenue-driven private sector. An example is infectious and communicable diseases. We are all aware of the crucial role played by the communicable disease center (CDC) when SARS struck in 2003.

Public provision of medical services also means that the decision to site medical facilities in certain locations are unlikely to be affected by economic factors such as whether the flow of patients will generate enough revenue to cover the cost or the economic status of the people in the surrounding areas. Additionally, by keeping fees affordable, public provision acts as a check to the private sector so as to prevent them from charging exorbitant fees that are out of reach to some segments of the society. In essence, public provision results in more equity, which I think should be the case for any society when it comes to basic medical services.

Obviously, public provision is not a silver bullet and it has its disadvantages as well. Many people have simplified the debates into equity versus efficiency. As public provision is not revenue-driven, services may be below that provided by private sector. While I have not experienced anything in Singapore that makes me question the efficiency of the public medical services, this does not mean that status quo will be maintained in the future. In the UK for example, patients have to wait for days, weeks and even months before they meet their National Health Service (NHS) consultants. Specifically for UK, the fact that patients do not have to pay consultation fees means self-censoring is non-existent and visits to local clinics appear to be their first course of action. This lethal combination of poor efficiency and waiver of consultation fees has led people to question whether equity has saved more lives or instead, caused more deaths.

Of more relevance to the current issues is the view that Government resources are limited. Any savings that can be obtained through privatization of medical services is a good thing as these resources could be used for other purposes, which the Government deemed or justified to be more important.

Likewise, leaving the private sector to provide medical services is not a silver bullet. While the disadvantages of public provision can be overcome, private sector by itself will not embrace the reasons why medical services have been mostly public driven in the first place.

A sensible model for provision of medical services is perhaps a combination of public and private sector whereby equity and efficiency can co-exist and patients have the flexibility to choose her most preferred type of services depending on her medical conditions at that point in time.

This compromise may not be a novel idea to many people. Afterall, Singapore’s healthcare sector already has a good mix of public and private players. In other words, this model has been achieved. To this, I think I would add the word ‘to a certain extent’ because this is certainly not the end of the road. There are still many rooms for improvements pertaining to this synergy. In the long run, the Government may want to pre-empt a situation whereby Singapore is presented with the healthcare dilemma faced by many developed economies now. Coming from the perspective of the Government, the more relevant question is how the private sector can be given a bigger share of the pie without affecting too much the basic tenet of public provision.

Several options can be explored to achieve this outcome. Through its land planning, Government can effectively pinpoint the best locations to site medical facilities. Instead of choosing locations based on revenue considerations, private sector has to choose designated locations. In doing so, the Government has ensured that people in different parts of Singapore are not disadvantaged when it comes to obtaining medical services. A good example is the Khoo Teck Phuat hospital.

Related to the issue of location is consolidation. In a further attempt to cut down spending, the UK has decided to close down several medical facilities that are deemed to be replicative. However, the huge distances across some facilities means that consolidation is not a viable option as it will affect provision in areas where the facilities have been closed down. In the context of Singapore, this is less of a problem because its small size and improving transport infrastructure essentially allow for more flexibility.

One worry with regards to consolidation is the strain that it will put on the remaining public medical facilities. To overcome this issue, regulations targeting both the patients as well as the private sector should be put in place. Pertaining to the patients, self-censoring behaviour can be instilled through for example the increase in the consultation fees. Of course, the possibility of exemption should always be in place to ensure equity. With regards to the private sector, the Government can establish a list of regulations that potential players should abide to if they win the tender to operate. One example is the requirement to allocate a certain percentage of their practice time to patients opting for public provision.

The options mentioned above are definitely non-exhaustive. Most importantly, their applicability in the context of Singapore should be thoroughly studied before they are implemented.

In conclusion, the issue on whether the Government should leave the provision of medical services to the private sector is a multi-faceted one and likely to be driven by the issue of the moment. Until now, no single country can claim that they have the perfect answer and debate by the two camps is likely to continue.

Wednesday, July 29, 2009

Balanced Measures, Please!

Many many weeks ago, while on a trip to Shenzhen (China), I experienced something I never thought I would in China. At that time, swine flu was in its early days of spreading and if I am not wrong, China had a few (<10) positive cases. Learning from its past experiences in handling SARS, the Chinese Government was very efficient in trying to contain swine flu.

The minute our plane landed at Shenzhen Baoan Airport, it was directed to an open parking space. We were then informed that in order to minimize the spread of swine flu, every passengers would have his/her temperature taken. No, not by air-stewardesses/ stewards, but by Chinese health authorities. Soon after, the cabin door opened and 3 men in masks and surgical gloves entered the plane. They began taking the temperature of each passenger. I must say I am very impressed with this method because detecting fever before people leave the plane allows the authorities to isolate potential carriers before they start to spread the virus to other people in the airport area. This can certainly reduce the transmission rate. In addition, when there’s a need to isolate people who have come into contact with the carriers, it is administratively simpler as authorities only need to quarantine the entire plane in the worst-case scenario without having to worry if some new and unknown carriers could have escaped the dragnet.

Unfortunately, my good impression ended there. Once we were cleared to leave the plane, we boarded the airport shuttle that was supposed to bring us to the main terminal building for immigration clearance. When we reached the terminal building, a security officer didn’t allow us to enter the building. Perhaps he was unconvinced that we were all free of swine flu. He told us to wait under the hot sun and admitted us one by one at a rate of 1 person for every 5 minutes. Meanwhile, we were given a health declaration form to fill up. I remembered clearly one section asked whether I had fever. My reaction was well, not now but maybe I would have one by the time I was allowed in because we were practically being barbecued under the afternoon sun.

Then, I started to recall that the Chinese Government had quarantined all Mexican passport-holders even though they didn’t exhibit any symptoms of swine flu. Were they just being paranoid? I understand that there’s a need to contain the virus but some measures were obviously too excessive and illogical. Instead of generating praises from around the world, it might end up doing the opposite. The Government should try to find a more balanced measures that would allow them to prevent the spread of swine flu and yet, did not make visitors feel unwelcome.

Thursday, May 14, 2009

Biologics or Not?

A white paper on Pharmaceuticals industry by PricewaterhouseCoopers (PWC) mentioned that 55 of the 106 (~52%) blockbusters on the market in 2007 were for specialist treatments. The report further stated that the sales of all specialist therapies could reach US$295-300 billion by end of 2008, accounting for 44% of worldwide spending on prescription pharmaceuticals. With these data, it is clear the demand for specialist medicines is climbing up. And so the most important question in the mind of most pharma industry CEOs is definitely: Should we venture into the business of specialist treatments?

From the economic perspective, the answer is clearly yes as shown by the data above. However, in our complex world, decisions are not made solely from a single perspective. The work of an economist, for example, always involves a balancing act, requiring one to defend his beliefs but at the same time, being mindful of the views of the opposition. This often results in economist supporting a bipartisan policy between his intended policy and that of his rivals, achieving success for those he represented but dampening the impact on those he didn’t represent.

This brings me to the main objective for writing this article: To challenge decision-makers to think twice before giving his nod to venture into this business. Note that I have made the assumption that venturing into the business of specialist treatment means venturing into biologics since it is the preferred type of drugs. First, the cost of developing a biologic (as this protein-based compound is called) is approximately US$1.2 billion, close to US$400m more than the average for a small molecule. Each biologic, on the other hand, is only capable of providing treatment to a mere 3% of the population. This will certainly increase the price of each unit of drug as the development cost of the biologic now has to be distributed over a smaller number of units, in accordance with the much smaller population that it treats. Without subsidy, only a select few can afford it. Can the revenue obtained from the smaller population cover the cost of development, marketing and etc?

A subsidy, on the other hand, does not equate to no troubles. The higher price is sure to increase the level of scrutiny of approving authorities before the subsidy is disbursed to the patients or the company. Can the company sustain itself when this arises? Will it encounter cash-flow problems?

I have also simplified the decision-making process by not taking into consideration the hot issue of “pay for performance”, which essentially shift the price determination activity from the company to payers (government and patients). Without “pay for performance”, all it takes is a patient in need of treatment and a health professional prescribing a drug for the company to obtain the revenue which it has fixed. With “pay for performance”, another factor has to be taken into consideration: outcome of the treatment. If it is below expectations, the revenue obtained may be drastically reduced.

Second, unlike small molecules, each biologic appears to have a broader range of activity and has higher probability of generating immune response. Anyone marketing it must have considerable scientific knowledge, in particular those relating to the risk, so as to communicate it clearly to the relevant people.

In addition, as the price determination activity has effectively shifted from company to payers, marketing and sales people have to engage these people beyond the conventional task of promoting their drugs. They must be able to feed the views of the payers to the various functions within the company, particularly the R&D function so that they can be taken as one of the many considerations of the development process.

Last but not least, many biologics have to be ordered when needed instead of being stock-up, as they are expensive (you don’t want to lock your money in inventories) and have short lifespan. They also must be transported under special conditions because they are prone to degradation. The development of the necessary infrastructures as well as the training of manpower to support all these are sure to further bump up the cost of specialized treatment.

In conclusion, the decision to venture into specialist treatments is not driven by economic perspective alone. It is imperative that many factors such as those shared above be taken into considerations.

Thursday, April 30, 2009

Please don’t sideline virus transmission rate

Since last week, the world has been once again under attack by small unseen enemy. The Swine Flu A/H1N1 virus has wrecked havoc in places around the world, starting from Mexico. Numerous organizations, including the WHO is on full drive to ‘really’ identify the virus so proper measures can be put in place. Among one of the first few findings is its low mortality rate as compared to H5N1 counterpart which held the world hostage in early 2003.

Personally, I would like to think of the low mortality rate being contributed by 2 factors. Firstly, the genetic makeup of the A/H1N1 virus is not so deadly to human as compared to H5N1. Secondly, it has nothing to do with the genetic makeup, meaning that the 2 viruses have roughly the same genetic makeup. It is the preparedness of the various organizations that had averted the high mortality rate this time. Anyway, either one is good because we can reduce deaths. But is mortality rate the only thing we should be worried about?

No. Besides mortality rate, we also have to look at the transmission rate. The reason is no matter how low the mortality rate is, if the virus has high transmission rate, it will infect large number of people. A small percentage of very large number of people is still millions of deaths in absolute number. Thus, unless the virus also have low transmission rate, people shouldn’t be too happy with the fact that it has low mortality rate. So, what’s the transmission rate like?

Judging from the quick spread of the virus from humans to humans within a week (currently, about 27 countries across 4 continents have either confirmed or suspected cases), I think it has a high transmission rate. To find out if it is higher than H5N1 virus or not, we need to do more analytical studies.

In conclusion, the virus mortality rate is only part of the story. To understand the entire story, we need more than mortality rate. In this case, transmission rate is definitely a major factor that needs to be taken into consideration.